Founded in 2013, Eachy Biopharmaceuticals, Ltd (江苏扬新生物医药有限公司) has over 10 years of experience in researching and developing in vitro diagnostic products for cardiac biomarkers, with a focus on detecting vulnerable plaques in atherosclerosis. With over 30 patents, we have launched products including MPO, HFABP, and Lp-PLA2 used by over 200 hospitals.
We are dedicated to advancing healthcare through continuous innovation.
Eachy is fully committed to providing diagnostic kits for the early detection and risk assessment of:
The current landscape lacks innovative Point-of-Care Testing (POCT) solutions for screening atherosclerotic plaque, assessing cardiovascular disease risk, and detecting early signs of Acute Myocardial Infarction (AMI) and Cerebrovascular Accident (CVA). Our mission is to address this gap in the POCT market by pioneering advanced diagnostic tools.
Early detection of acute coronary syndrome
Assess the risk of MACE after thrombolytic therapy or percutaneous coronary intervention in AMI
Identify ACS patients with negative cTn for future MACE
Predict risk of ACS in healthy adults over age of 35
Early warning - 6 months ahead
Predicts risk of MACE between 30 days - 6 months
Mid-late stage warning
Rising CRP correlates with higher mortality of ACS & MACE
Early Red Alert within first 1-3 hours after ACS
Rising H-FABP and cTnT within first 3 hours, rule out AMI
Early detection of DN within 2 hours of renal damage VS gold standard (detection after 2 days)*
↓ For business inquiries, please feel free to drop us a note and we will be in touch shortly. ↓
